Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRINCIPEN W/ PROBENECID vs ANTURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gonorrhea (uncomplicated)
Treatment of chronic gout,Prophylaxis of acute gouty attacks during initiation of allopurinol or uricosuric therapy,Off-label: Prevention of calcium oxalate calculi in hyperuricosuric patients
1.5-3 g IM q6h (20 mg/kg/day probenecid component).
200-400 mg orally twice daily
Ampicillin: 1-1.8 hours (prolonged to 4-6 hours with probenecid due to reduced renal clearance). Probenecid: 6-12 hours. Clinical context: extended half-life allows less frequent dosing.
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Ampicillin is metabolized by hydrolysis to penicilloic acid; probenecid undergoes hepatic metabolism via glucuronidation and oxidation.
Primarily hepatic oxidation and glucuronidation; minor CYP450 involvement.
Renal: ~60-80% of ampicillin excreted unchanged in urine via tubular secretion and glomerular filtration; probenecid reduces this to ~20-30%. Biliary/fecal: minor, <10%.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Ampicillin: 15-25% bound to albumin. Probenecid: 85-95% bound to albumin.
99% bound, primarily to albumin.
Ampicillin: 0.3-0.4 L/kg (distributes well into extracellular fluid, low CNS penetration unless inflamed meninges).
0.15–0.3 L/kg, indicating limited extravascular distribution; primarily remains in plasma and extracellular fluid.
Oral: 30-50% for ampicillin (enhanced by probenecid? probenecid does not significantly alter ampicillin absorption). Probenecid: nearly 100% oral.
Oral: Approximately 90% absorbed, but extensive first-pass metabolism reduces systemic bioavailability of parent drug to 30–40%; active sulfide metabolite contributes to efficacy.
Cr Cl 30-50 m L/min: 1.5 g IM q8h; Cr Cl 10-29 m L/min: 1.5 g IM q12h; Cr Cl <10 m L/min: 1.5 g IM q24h.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-50 m L/min, reduce dose by 50%. For Cr Cl >50 m L/min, no adjustment.
No adjustment required for mild to moderate impairment. Severe impairment (Child-Pugh C): consider reducing dose by 25-50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children 2-12 years: 50 mg/kg/day IM in 4 divided doses (probenecid component 25 mg/kg/day). Maximum single dose 2 g.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Reduce dose based on renal function; avoid if Cr Cl <30 m L/min due to probenecid accumulation. Monitor for CNS toxicity.
Start at low end of dosing range (200 mg twice daily); monitor renal function. Caution due to increased sensitivity and renal impairment.
None.
None.
Hypersensitivity reactions including anaphylaxis,Severe cutaneous adverse reactions (SCARs),C. difficile-associated diarrhea,Renal impairment (dose adjustment for ampicillin),Sodium overload with high doses,Allergic cross-reactivity with cephalosporins
Acute gouty attacks may occur during initiation; prophylactic colchicine or NSAIDs recommended,Monitor renal function; dose adjustment in renal impairment,Avoid in patients with high urinary uric acid output to prevent uric acid stones,May potentiate warfarin; monitor INR,Cross-allergenicity with sulfonamides possible
Hypersensitivity to penicillins or probenecid,History of cholestyramine or uricosuric agent hypersensitivity,Severe renal impairment (Cr Cl < 30 m L/min) for probenecid-containing products,Blood dyscrasias or uric acid calculi (probenecid)
Severe renal impairment (Cr Cl <50 m L/min),History of hypersensitivity to sulfinpyrazone or sulfonamides,Active peptic ulcer disease,Blood dyscrasias,Uric acid nephropathy or stone formation
Take with food or milk to reduce gastrointestinal upset. Avoid high-fat meals as they may delay absorption of ampicillin. Probenecid is not affected by food; however, maintain adequate hydration to prevent crystalluria.
Avoid alcohol as it increases uric acid levels and may decrease drug efficacy. Maintain adequate hydration; avoid excessive intake of high-purine foods (e.g., organ meats, sardines, anchovies) to help control gout.
FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratogenic effects. Second/third trimester: Use caution due to potential for altered fetal gut flora. Peripartum: Risk of kernicterus in neonates if maternal hyperbilirubinemia.
Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. However, due to its potential to inhibit platelet aggregation, use during pregnancy, especially near term, may increase the risk of maternal and fetal hemorrhage. First trimester: No specific fetal risks identified, but caution advised. Second trimester: Risks unclear; avoid unless necessary. Third trimester: Potential for premature closure of ductus arteriosus (unlikely as it is not an NSAID) and bleeding risk; avoid near term.
Ampicillin excreted in breast milk in low levels (M/P ratio 0.02-0.1); probenecid probably excreted but data limited. Compatible with breastfeeding; monitor infant for diarrhea, rash, or candidiasis. Theoretical risk of kernicterus in jaundiced infants if probenecid displaces bilirubin.
Sulfinpyrazone is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not well established but is likely low (<0.2). Due to potential adverse effects in the nursing infant (e.g., bleeding risk, interference with platelet function), caution is recommended. The benefits of breastfeeding should be weighed against the potential risks, and alternative therapies considered.
Increased renal clearance in pregnancy may reduce ampicillin levels; consider higher doses or more frequent intervals for severe infections. Probenecid dose adjustment not typically required, but monitor for efficacy. Use standard doses for UTI unless resistant organisms suspected.
Pregnancy can alter pharmacokinetics of drugs due to increased plasma volume, renal blood flow, and hepatic metabolism. For sulfinpyrazone, no specific dose adjustment guidelines are established for pregnancy. Given its uricosuric action, the increased glomerular filtration rate during pregnancy may enhance clearance, potentially requiring higher doses to maintain therapeutic effect. However, due to potential risks, use should be avoided if possible. If used, monitor serum uric acid levels and adjust dose accordingly, starting with the lowest effective dose.
Principen w/ Probenecid combines ampicillin, a broad-spectrum penicillin, with probenecid to prolong ampicillin serum levels by inhibiting renal tubular secretion. Use in penicillin-allergic patients is contraindicated. Probenecid may reduce excretion of other drugs (e.g., methotrexate, NSAIDs). Monitor renal function; probenecid is contraindicated in patients with uric acid kidney stones or blood dyscrasias. Administer with food if GI upset occurs. Synergistic with aminoglycosides but physically incompatible; do not mix in IV solutions.
Anturane (sulfinpyrazone) is a uricosuric agent used for chronic gout. It is contraindicated in patients with peptic ulcer disease due to GI irritation. Monitor renal function and uric acid levels. Avoid use in patients with a history of uric acid stones; maintain high fluid intake to prevent stone formation. Not effective in acute gout attacks. Discontinue at least 48 hours before surgery to avoid bleeding risk due to antiplatelet effects.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course to prevent antibiotic resistance.,May cause diarrhea; contact your doctor if it is severe or contains blood.,Avoid alcohol while taking this medication.,Inform your doctor if you have kidney disease, gout, or a history of penicillin allergy.,Probenecid may increase effects of warfarin; monitor for bleeding.,Drink plenty of fluids to prevent kidney stones while on probenecid.
Take with food or milk to reduce stomach upset.,Drink at least 8 glasses of water daily to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce drug effectiveness.,Report any signs of bleeding (bruising, black stools) or stomach pain.,Do not stop suddenly without consulting your doctor.,This drug is not for acute gout attacks; continue other medications as prescribed.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRINCIPEN W/ PROBENECID vs ANTURANE, answered by our medical review team.
PRINCIPEN W/ PROBENECID is a Uricosuric that works by Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.. ANTURANE is a Uricosuric that works by Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRINCIPEN W/ PROBENECID and ANTURANE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRINCIPEN W/ PROBENECID is: 1.5-3 g IM q6h (20 mg/kg/day probenecid component).. The standard adult dose of ANTURANE is: 200-400 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRINCIPEN W/ PROBENECID and ANTURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRINCIPEN W/ PROBENECID is classified as Category A/B. FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratoge. ANTURANE is classified as Category C. Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.